Consistent with our in vitro findings, FL/GM-DCs exhibited significantly greater therapeutic efficacy than GM/IL4-DCs in both B16F10 melanoma and MC38 colorectal cancer models, whether applied as a tumor vaccine or as a therapeutic intervention after tumor onset. The gene discussed is IL4; the disease is neoplasm.